ASH 2021 | Stem cell collection in patients with multiple myeloma treated with anti-CD38 monoclonal antibodies

Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, talks on stem cell collection in patients with newly diagnosed multiple myeloma treated with daratumumab-based treatment regimens, highlighting data from the CASSIOPEIA (NCT02541383), GRIFFIN (NCT02874742), and MASTER (NCT03224507) trials. The CASSIOPEIA and GRIFFIN studies have shown that adding an anti-CD38 monoclonal antibody to immunomodulatory drug (IMiD)-based induction platforms reduces the median stem cell yield and increases the rate of utilization of plerixafor in patients treated with this agent. Nevertheless, this has not had a significant clinical impact on most patients treated with quadruplet therapy. Dr Voorhees emphasizes the importance of conducting further studies to investigate the effect of the duration of induction regimens on stem cell mobilization, and he also provides advice for patients treated with daratumumab plus lenalidomide, bortezomib and dexamethasone (D-RVd) induction therapy who are going to receive a transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.